Literature DB >> 11604689

[An assessment of low-dose high resolution CT in the detection of benign asbestos-related pleural abnormalities].

J L Michel1, C Reynier, G Avy, J J Bard, D Gabrillargues, P Catilina.   

Abstract

PURPOSE: To assess the reliability of low-dose high-resolution computed tomography (HRCT) in the detection of benign asbestos-related pleural abnormalities.
METHODS: Fourty-one patients exposed to asbestos were imaged on two occasions; the first time with conventional HRCT parameters: 140kVp, 220mAs; the second time with low-dose HRCT parameters: 120kVp, 60mAs.
RESULTS: The qualitative assessment dit not show any difference in the visibility of benign pleural abnormalities from one technique to the other in 98% cases.
CONCLUSION: The detection of pleural plaques and thickening did not vary with the two scanning protocols and, when compared with conventional HRCT, low-dose HRCT allows reduced radiation exposure by at least 76.5%, with an absorbed dose close to that delivered when using conventional chest radiography. Nevertheless, low-dose HRCT is a complementary study to helical acquisitions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11604689

Source DB:  PubMed          Journal:  J Radiol        ISSN: 0221-0363


  3 in total

Review 1.  Multislice CT: update on radiation and screening.

Authors:  Mannudeep K Kalra; Michael M Maher; Sanjay Saini
Journal:  Eur Radiol       Date:  2003-12       Impact factor: 5.315

2.  Optimal dose levels in screening chest CT for unimpaired detection and volumetry of lung nodules, with and without computer assisted detection at minimal patient radiation.

Authors:  Andreas Christe; Zsolt Szucs-Farkas; Adrian Huber; Philipp Steiger; Lars Leidolt; Justus E Roos; Johannes Heverhagen; Lukas Ebner
Journal:  PLoS One       Date:  2013-12-26       Impact factor: 3.240

Review 3.  Radiation exposure from chest CT: issues and strategies.

Authors:  Mannudeep K Kalra; Michael M Maher; Stefania Rizzo; David Kanarek; Jo-Anne O Shepard; Jo-Anne O Shephard
Journal:  J Korean Med Sci       Date:  2004-04       Impact factor: 2.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.